Dr Rajeev Venkayya to head Takeda’s new vaccine business

pharmafile | December 9, 2011 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Takeda 

Takeda will establish a new vaccine business division in January next year and will appoint Dr Rajeev Venkayya as its leader of the division.

Assuming office as the head of the new division on 15 January, Dr Rajeev Venkayya currently serves as director of vaccine delivery in the global health programme at the Bill & Melinda Gates Foundation, where he oversees the Foundation’s efforts in polio eradication and its investment in the Global Alliance for Vaccines and Immunization (GAVI).

Trained as a physician in pulmonary and critical care medicine, Dr Venkayya was previously the special assistant to the president for biodefense at the White House.

The company’s recent efforts in the vaccine business include clinical testing of the Haemophilus Influenzae type b (Hib) vaccine, and the development of a human papillomavirus (HPV) vaccine. 

Advertisement

Related Content

Von Willebrand disease – increasing awareness and access to vital care

Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …

Combination treatments: Takeda’s Implementation Framework and the broader landscape

Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …

Takeda presents positive results from trial of chronic kidney disease treatment

Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat …

The Gateway to Local Adoption Series

Latest content